Speciality Medicines Ipo
Speciality Medicines IPO Review & Key Points
Review:
IPO Lead Managers aka Merchant Bankers
Unicon Capital Services Pvt. Ltd.
| Application | Lot Size | Shares | Amount |
| Retail Minimum | 2 | 2,000 | ₹2,48,000 |
| Retail Maximum | 2 | 2,000 | ₹2,48,000 |
| S-HNI Minimum | 3 | 3,000 | ₹3,72,000 |
| S-HNI Maximum | 8 | 8,000 | ₹9,92,000 |
| B-HNI Minimum | 9 | 9,000 | ₹11,16,000 |
| Investor Category | Share Offered | Shares (%) |
| Anchor Investor | – Shares | -% |
| QIB (Ex. Anchor) | – Shares | 2% |
| NII Shares Offered | – Shares | 49% |
| Retail Shares Offered | – Shares | 49% |
| IPO Open Date: | March 20, 2026 |
| IPO Close Date: | March 24, 2026 |
| Basis of Allotment: | March 25, 2026 |
| Refunds: | March 27, 2026 |
| Credit to Demat Account: | March 27, 2026 |
| IPO Listing Date: | March 30, 2026 |
| IPO Bidding Cut-off Time: | March 24, 2026 – 5 PM |
| Particular | Shares | % Share |
| Promoter Holding Pre Issue | 64,35,796 | 59.28% |
| Promoter Holding Post Issue | 87,85,796 | -% |
| Purpose | Crores |
| Setting up of the Research and Development (R&D) Centre | ₹13.31 |
| Product registration in the international markets | ₹2.89 |
| Repayment/ Prepayment, in full or part, of certain borrowings availed by the Company | ₹1.75 |
| To Meet Working Capital Requirements | ₹12.00 |
| General Corporate Purpose | ₹- |
| Period Ended | Revenue | Expense | PAT | Assets |
| 2024 | ₹27.66 | ₹23.10 | ₹2.93 | ₹22.68 |
| 2025 | ₹58.54 | ₹49.85 | ₹8.61 | ₹39.98 |
| Oct 2025 | ₹36.93 | ₹30.80 | ₹6.06 | ₹45.57 |
| KPI | Values |
| ROE: | 37.85% |
| ROCE: | 33.39% |
| EBITDA Margin: | 15.60% |
| PAT Margin: | 14.77% |
| Debt to equity ratio: | 0.17 |
| Earning Per Share (EPS): | ₹14.10 (Basic) |
| Price/Earning P/E Ratio: | N/A |
| Return on Net Worth (RoNW): | 28.42% |
| Net Asset Value (NAV): | ₹47.07 |
| Company | EPS | PE Ratio | RoNW % | NAV | Income |
| Remus Pharmaceuticals Limited | 65.21 | 12.25 | 15.02% | 434.25 | 620.36 Cr. |
| Trident Lifeline Limited | 10.22 | 27.59 | 18.23% | 56.05 | 86.96 Cr. |
| Mono Pharmacare Limited | 1.75 | 13.87 | 9.90% | 17.66 | 168.34 Cr. |
| Cookie | Duration | Description |
|---|---|---|
| cookielawinfo-checkbox-analytics | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics". |
| cookielawinfo-checkbox-functional | 11 months | The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional". |
| cookielawinfo-checkbox-necessary | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary". |
| cookielawinfo-checkbox-others | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other. |
| cookielawinfo-checkbox-performance | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance". |
| viewed_cookie_policy | 11 months | The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data. |
| IPO Open Date | March 20, 2026 |
| IPO Close Date | March 24, 2026 |
| Face Value | ₹10 Per Equity Share |
| IPO Price Band | ₹117 to ₹124 Per Share |
| Issue Size | Approx ₹29.14 Crores |
| Fresh Issue | Approx ₹29.14 Crores |
| Issue Type | Book build Issue |
| IPO Listing | BSE SME |
| DRHP Draft Prospectus | |
| RHP Draft Prospectus |